Loading...
Loading...
PTPI| Name | Value |
|---|---|
| Revenues | 1,388.8K |
| Cost of Revenue | 331.8K |
| Gross Profit | 1,057.0K |
| Operating Expense | 1,171.0K |
| Operating I/L | -1,503.0K |
| Other Income/Expense | 1,886.0K |
| Interest Income | 151.8K |
| Pretax | 382.9K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,163.0K |
Petros Pharmaceuticals, Inc. specializes in men's health therapeutics, primarily focusing on the commercialization and development of Stendra, a prescription medication for erectile dysfunction (ED). Additionally, the company is involved in the development and commercialization of H100, a patented topical formulation for the treatment of acute Peyronie's disease. Petros Pharmaceuticals also markets a line of ED products in the form of vacuum erection device products, catering to the needs of individuals seeking solutions for men's health issues.
